Zydus Lifesciences Limited — Updates, 28-05-2025: Press Release

Zydus has announced a board meeting to discuss the financial results for the quarter and half-year. Its novel oral NLRP3 inhibitor, Usnoflast, for ALS treatment, received USFDA Fast Track and Orphan Drug designations, accelerating development and offering market exclusivity. The ongoing Phase 2(b) trial highlights Zydus’ focus on neuroscience therapies with strong potential in neurodegenerative disease markets.